anti-doping analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
strand An individual chain of nucleotides comprising a nucleic acid polymer, existing either independently (in which case the nucleic acid molecule is said to be single-stranded) or base-paired in a duplex with another, separate strand (in which case it is said to be double-stranded).
== Junior career == Zverev played his first junior match in January 2011 at the age of 13 at a grade 4 tournament in Poland. Near the beginning of 2012, Zverev won his first ITF title at the Fujairah Junior Championships, a low-level Grade 4 tournament in the United Arab Emirates. He would pick up a lower level Grade 5 title at the Oman International Junior 2 a few weeks later, which led him to begin competing in higher-level events shortly before his 15th birthday. He did not have much success at tournaments that were Grade 2 and above until the following year when he reached back-to-back doubles finals with Spencer Papa at the Grade A Copa Gerdau and the Grade 1 USTA International Spring Championships. Zverev's early-season success in doubles proved to be the precursor of a major improvement in singles as well. During the European clay court season, he won his first Grade 1 title over Andrey Rublev at the Open International Junior de Beaulieu-sur-Mer. He followed up that performance with his first Grade A title at the Trofeo Bonfiglio a month later, becoming the youngest boys' singles champion in the tournament's history. He also finished runner-up at the 2013 French Open to Cristian Garín. Zverev had some grass court success as well, finishing runner-up to Nick Kyrgios at the Junior International Roehampton. However, he needed to retire at Wimbledon due to a shoulder injury. Zverev came close to reaching another major boys' singles final at the 2013 Junior US Open, but was defeated by the eventual champion Borna Ćorić in the semifinals.
The waning loyalty of the Cossacks, and the szlachta's arrogance towards them, resulted in several Cossack uprisings against the Polish–Lithuanian Commonwealth in the early 17th century. Finally, the King's adamant refusal to accede to the demand to expand the Cossack Registry prompted the largest and most successful of these: the Khmelnytsky Uprising, that began in 1648. Some Cossacks, including the Polish szlachta in Ukraine, converted to Eastern Orthodoxy, divided the lands of the Ruthenian szlachta, and became the Cossack szlachta. The uprising was one of a series of catastrophic events for the Commonwealth, known as The Deluge, which greatly weakened the Polish-Lithuanian Commonwealth and set the stage for its disintegration 100 years later. Influential relatives of the Ruthenian and Lithuanian szlachta in Moscow helped to create the Russian–Polish alliance against Khmelnitsky's Cossacks, portrayed as rebels against order and against the private property of the Ruthenian Orthodox szlachta. Don Cossacks' raids on Crimea left Khmelnitsky without the aid of his usual Tatar allies. From the Russian perspective, the rebellion ended with the 1654 Treaty of Pereyaslav, in which, in order to overcome the Russian–Polish alliance against them, the Khmelnitsky Cossacks pledged their loyalty to the Russian Tsar. In return, the Tsar guaranteed them his protection; recognized the Cossack starshyna (nobility), their property, and their autonomy under his rule; and freed the Cossacks from the Polish sphere of influence and the land claims of the Ruthenian szlachta.
=== Xenobiotics === Numerous drugs can raise GGT levels, including phenobarbitone and phenytoin. GGT elevation has also been occasionally reported following nonsteroidal anti-inflammatory drugs (including aspirin), St. John's wort and kava.
Sources: en.wikipedia.org
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal cancers and has a 5-year survival rate of 13%. Pancreatic adenocarcinoma cells resemble pancreatic ductal cells. Both cell groups show tubule formation, cuboidal shape, and ductal markers. Additionally, acinar and endocrine cells have often been found in many of these cancers, demonstrating plasticity and the possibility that the initial target cells are pancreas progenitor cells. Moreover, human tumors usually go with lower-grade lesions that are called pancreatic intraepithelial neoplasias (PanINs) and are in ducts. Because these lesions are in ducts, this means that it is possible that the beginning target cells are ductal cells.
Mkhedrioni relied on illegal sources of income (targeting gasoline supplies) and exploited connections with Moscow's Georgian underworld. Mkhedrioni members were often accused of criminal activity, extorting "protection money" from businesses in areas which they effectively controlled, operating roadblocks where drivers would be "fined", smuggling drugs and committing robberies. By 1991, the Mkhedrioni was claimed to have had about 1,000 fighters and 10,000 associate members – considerably more than the official state National Guard. Despite Gamsakhurdia and Ioseliani sharing a broadly similar nationalist outlook, the two men fell out badly shortly after Gamsakhurdia came to power in November 1990. In February 1991, Ioseliani was imprisoned without trial, along with many of his supporters, and the Mkhedrioni was banned. In August 1991, just after the Soviet coup attempt, Gamsakhurdia sacked Tengiz Kitovani, the commander of Georgia's National Guard, and his Prime Minister Tengiz Sigua resigned around the same time. Kitovani soon formed an anti-Gamsakhurdia alliance with Sigua and the imprisoned Ioseliani. In December 1991, Kitovani's supporters released Ioseliani from jail and launched a violent coup d'état against the Gamsakhurdia government in alliance with the Mkhedrioni. Intense gun battles took place in the streets of Tbilisi between the rebels and "Zviadists" holed up in the state parliament building during December 1991 – January 1992, which ended with Gamsakhurdia fleeing to the breakaway Russian republic of Chechnya. At least 100 people were killed in the fighting.
Eucalyptus globulus subsp. bicostata (Maiden, Blakely & Simmonds) J.B.Kirkp. (formerly Eucalyptus bicostata), commonly known as Victorian blue gum or eurabbie, has sessile flower buds arranged in groups of three; Eucalyptus globulus Labill. subsp. globulus, commonly known as Tasmanian blue gum, has flower buds arranged singly in leaf axils; Eucalyptus globulus subsp. maidenii (F.Muell.) J.B.Kirkp. (formerly Eucalyptus maidenii), commonly known as Maiden's gum has flower buds arranged in groups of seven Eucalyptus globulus subsp. pseudoglobulus (Naudin) J.B.Kirkp. (formerly Eucalyptus globulus var. pseudoglobulus), commonly known as Victorian eurabbie has pedicellate flower buds arranged in groups of three.
Other studies have suggested that perchlorate can also be formed by lightning activated oxidation of chloride aerosols (e.g., chloride in sea salt sprays), and ultraviolet or thermal oxidation of chlorine (e.g., bleach solutions used in swimming pools) in water.
== Mechanism == Aspartate transaminase, as with all transaminases, operates via dual substrate recognition; that is, it is able to recognize and selectively bind two amino acids (Asp and Glu) with different side-chains. In either case, the transaminase reaction consists of two similar half-reactions that constitute what is referred to as a ping-pong mechanism. In the first half-reaction, amino acid 1 (e.g., L-Asp) reacts with the enzyme-PLP complex to generate ketoacid 1 (oxaloacetate) and the modified enzyme-PMP. In the second half-reaction, ketoacid 2 (α-ketoglutarate) reacts with enzyme-PMP to produce amino acid 2 (L-Glu), regenerating the original enzyme-PLP in the process. Formation of a racemic product (D-Glu) is very rare. The specific steps for the half-reaction of enzyme-PLP + aspartate
Sources: en.wikipedia.org
Following four months Transport was absorbed into the new "monster ministry" of the Department for the Environment, under Heseltine's ally Peter Walker. Heseltine was still responsible for transport, but also for local government reform, covered in the Local Government Act 1972. Redcliffe-Maude's proposals for unitary councils (i.e. merging the two layers of county and borough/district councils) were abandoned. Many historic counties were abolished. Large Metropolitan counties were created around the big cities, but many smaller cities lost their county borough status. One such was Plymouth, the eastern suburbs of which lay in Heseltine's seat of Tavistock. Plymouth opinion was particularly angry that education was now to be run by Devon County Council in Exeter, 40 miles away. Heseltine declined to support a campaign by Plymouth MP Dame Joan Vickers to create a Tamarside Metropolitan county, and was rebuked by Sir Henry Studholme, his predecessor as MP for Tavistock, for declining to support (on the grounds that as minister he might have to adjudicate any dispute) Plymouth Council's attempt to buy more land near Sparkwell to develop light industry under its control.
Pea protein is a food product and protein supplement derived and extracted from yellow and green split peas, Pisum sativum. It can be used as a dietary supplement to increase an individual's protein or other nutrient intake, or as a substitute for other food products (e.g. the substitution of dairy milk by pea milk). As a powder, it is used as an ingredient in food manufacturing, such as a thickener, foaming agent, or an emulsifier. It is extracted in a powder form and can be processed and produced in different ways:
==== Near-death experiences ==== A 2018 study found significant relationships between DMT experiences and near-death experiences (NDE). A 2019 large-scale study pointed that ketamine, Salvia divinorum, and DMT (and other classical psychedelic substances) may be linked to NDEs due to the semantic similarity of reports associated with the use of psychoactive compounds and NDE narratives, but the study concluded that with the current data it is neither possible to corroborate nor refute the hypothesis that the release of an endogenous ketamine-like neuroprotective agent underlies NDE phenomenology.
=== Secondary and tertiary structures === Chymopapain's structure was solved by X-ray diffraction techniques. Analysis of this structure showed chymopapain to have 7 alpha helix regions, 10 beta sheet regions and 2 loop turns. These 2 turns are the main difference between chymopapain's structure and other papaya proteinase proteins such as papain or caricain, which have similar conformations. Besides, chymopapain presents 3 disulfide bonds as post-traducional modifications stablished between residues 156–197, 190–229 and 287–338.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.